Filter
708
Filtered Results: 708
Text search:
Licensed
pharmaceutical
products
Featured
Recommendations
65
New Publications
181
Language
Document type
No document type
294
Studies & Reports
184
Guidelines
109
Manuals
57
Strategic & Response Plan
40
Training Material
9
Fact sheets
9
Situation Updates
5
Resource Platforms
1
Countries / Regions
Global
37
Kenya
30
India
17
Nigeria
16
South Africa
14
Uganda
14
Ethiopia
14
Ghana
13
Western and Central Europe
12
Liberia
12
Sierra Leone
11
Rwanda
10
Zimbabwe
9
Philippines
9
Latin America and the Carribbean
9
Nepal
8
Ukraine
8
Tanzania
8
Zambia
8
Africa
7
Eastern Europe and Central Asia
7
Bangladesh
7
Malawi
6
Myanmar / Burma
6
Syria
5
West and Central Africa
5
South–East Asia Region
5
East and Southern Africa
5
Thailand
4
Cambodia
4
Namibia
4
Botswana
4
Benin
3
Laos
3
Senegal
3
Asia
3
Middle East and North Africa
3
Indonesia
3
Eswatini/ Swaziland
3
North Macedonia
2
Tajikistan
2
Cameroon
2
Burkina Faso
2
Mozambique
2
Congo, Democratic Republic of
2
Western Pacific Region
2
North America
2
United Kingdom
2
Eastern Europe
2
Timor Leste/ East Timor
1
Serbia
1
Lesotho
1
Kazakhstan
1
Iran
1
Albania
1
Kyrgyzstan
1
Uzbekistan
1
Mongolia
1
Bulgaria
1
Guinea
1
Armenia
1
Haiti
1
Venezuela
1
Gabon
1
Vietnam
1
Brazil
1
Moldova
1
Russia
1
Sudan
1
Georgia
1
Mali
1
Angola
1
South Sudan
1
Somalia
1
Pakistan
1
Authors & Publishers
Publication Years
Category
Countries
264
Clinical Guidelines
70
Public Health
50
Key Resources
27
Pharmacy & Technologies
24
Women & Child Health
20
Capacity Building
4
Toolboxes
AMR
83
Pharmacy
71
COVID-19
47
Mental Health
30
NTDs
30
TB
28
HIV
27
Planetary Health
23
Rapid Response
22
Health Financing Toolbox
19
Caregiver
18
Global Health Education
17
Conflict
15
NCDs
13
Ebola & Marburg
9
Specific Hazards
5
Refugee
3
Disability
3
Polio
2
Natural Hazards
1
Social Ethics
1
Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV
recommended
Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum. This disease is highly endemic in some regions of North America, Central America, and South America and is also reported in certain countries of Asia and Africa. It often affects people with impaired immunity, including people ...
2016-2018 Early implementation,
This report presents 2015 data on the consumption of systemic antibiotics from 65 countries and areas, contributing to our understanding of how antibiotics are used in these countries. In addition, the report documents early efforts of the World Health Organization (...
The purpose of this guidance is to assist WHO Member States, and other stakeholders, in the establishment and development of programmes of integrated surveillance of antimicrobial resistance in foodborne bacteria (i.e., bacteria commonly transmitted by food). In this guidance, “integrated surveill...
The infectious disease burden in India is among the highest in the world. A large amount of antibiot-ics are consumed in fighting infections, some of them saving lives, but every use adding to antibiotic resistance in bacteria. Antibiotic use is increasing steadily (table 1), particularly ...
The two-year impact report for the Access to COVID-19 Tools (ACT) Accelerator details impact, case studies and timelines of key milestones for the Diagnostics, Therapeutics and Vaccines pillars, as well as the Health Systems and Response Connector.
Access to health workers who are fit for purpose, motivated and protected is a fundamental force of health service delivery and the achievement of universal health coverage and the health and health-related Sustainable Development Goals. Data and knowledge of the distribution, skill mix and future d...
WHO and UNITAID
in collaboration with IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials) network, PENTA (Paediatric European Network for Treatment of AIDS) foundation and experts from the Paediatric Antiretroviral Working Group
This report presents an analysis of antibacterial agents in preclinical (third annual review) and clinical (fifth annual review) development. The analysis covers traditional (direct-acting small molecules) and non-traditional antibacterial agents in development worldwide. It evaluates to what extent...
This document is a guide defining requirements for quality and safety for malaria rapid diagnostic testing services to safeguard the quality of the results, the safety of the operators and patients and that of the environment for use by national malaria control programmes, regulators, implementers a...
WHO’s Country Cooperation Strategy (CCS) defines the Organization’s medium-term vision for working in and with a particular country. The CCS, developed in the context of global and national health priorities, examines the overall health situation in a country, including the state of the health s...
PMPB/INS-GUIDE/01
The Global Strategy for Tuberculosis Research and Innovation will support the efforts of governments and other stakeholders to accelerate TB research and innovation, and improve equitable access to the benefits of research.
Availabl in Arabic, Chinese, English, French, Spanish and Russian
Vaccines are powerful weapons in the fight against pandemic viruses as shown by responses to both the 2009 H1N1 influenza and the COVID-19 pandemics. However, planning for accessing, allocating and deploying vaccines in a pandemic situation is a complex endeavour, beset with multiple challenges at a...
Application of a One Health approach .
The present guidance was developed with the support of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) to assist countries and other stakeholders in the establishment and development of programmes of integrated surveillan...
Urbanization, land use, global trade and industrialization have led to profound and negative impacts on nature, biodiversity and ecosystems across the world. The ongoing depletion of natural resources not only afects environmental conditions but also has an enormous impact on the well-being and secu...
The World Health Organization (WHO) and the global community of countries, partners, donors, technical experts, scientists and field implementation teams continue to work towards the ultimate goal of a world free of the burden of neglected tropical diseases (NTDs).
2nd edition .
This Framework applies to the sharing of H5N1 and other influenza viruses with human pandemic potential and the sharing of benefits. This Framework does not apply to seasonal influenza viruses or other non-influenza pathogens or biological substances that may be contained in clinical ...
High prices, hard-to-access human insulin, few insulin producers, and weak health systems are just some of the barriers that people with diabetes face a century after insulin was discovered, WHO notes in a new report
